128 related articles for article (PubMed ID: 26271547)
41. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcome in resected non-small cell lung cancer patients.
Ragusa M; Vannucci J; Ludovini V; Bianconi F; Treggiari S; Tofanetti FR; Flacco A; Colella R; Sidoni A; Crinò L; Puma F
Am J Clin Oncol; 2014 Aug; 37(4):343-9. PubMed ID: 23357969
[TBL] [Abstract][Full Text] [Related]
42. Genetic polymorphism in the epidermal growth factor receptor gene predicts outcome in advanced non-small cell lung cancer patients treated with erlotinib.
Winther-Larsen A; Nissen PH; Jakobsen KR; Demuth C; Sorensen BS; Meldgaard P
Lung Cancer; 2015 Nov; 90(2):314-20. PubMed ID: 26386832
[TBL] [Abstract][Full Text] [Related]
43. The role of smoking status on the progression-free survival of non-small cell lung cancer patients harboring activating epidermal growth factor receptor (EGFR) mutations receiving first-line EGFR tyrosine kinase inhibitor versus platinum doublet chemotherapy: a meta-analysis of prospective randomized trials.
Hasegawa Y; Ando M; Maemondo M; Yamamoto S; Isa S; Saka H; Kubo A; Kawaguchi T; Takada M; Rosell R; Kurata T; Ou SH
Oncologist; 2015 Mar; 20(3):307-15. PubMed ID: 25657199
[TBL] [Abstract][Full Text] [Related]
44. Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.
Liu G; Gurubhagavatula S; Zhou W; Wang Z; Yeap BY; Asomaning K; Su L; Heist R; Lynch TJ; Christiani DC
Pharmacogenomics J; 2008 Apr; 8(2):129-38. PubMed ID: 17375033
[TBL] [Abstract][Full Text] [Related]
45. EGFR CA repeat polymorphism predict clinical outcome in EGFR mutation positive NSCLC patients treated with erlotinib.
Winther Larsen A; Nissen PH; Meldgaard P; Weber B; Sorensen BS
Lung Cancer; 2014 Sep; 85(3):435-41. PubMed ID: 25017413
[TBL] [Abstract][Full Text] [Related]
46. CYP1A1*2A polymorphism as a predictor of clinical outcome in advanced lung cancer patients treated with EGFR-TKI and its combined effects with EGFR intron 1 (CA)n polymorphism.
Nie Q; Yang XN; An SJ; Zhang XC; Yang JJ; Zhong WZ; Liao RQ; Chen ZH; Su J; Xie Z; Wu YL
Eur J Cancer; 2011 Sep; 47(13):1962-70. PubMed ID: 21616658
[TBL] [Abstract][Full Text] [Related]
47. Differential mutation profiles and similar intronic TP53 polymorphisms in asbestos-related lung cancer and pleural mesothelioma.
Andujar P; Pairon JC; Renier A; Descatha A; Hysi I; Abd-Alsamad I; Billon-Galland MA; Blons H; Clin B; Danel C; Debrosse D; Galateau-Sallé F; Housset B; Laurent-Puig P; Le Pimpec-Barthes F; Letourneux M; Monnet I; Régnard JF; Validire P; Zucman-Rossi J; Jaurand MC; Jean D
Mutagenesis; 2013 May; 28(3):323-31. PubMed ID: 23435014
[TBL] [Abstract][Full Text] [Related]
48. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
49. A novel BIM deletion polymorphism: implications and lessons for cancer targeted therapies.
Soh S; Ong ST
Rinsho Ketsueki; 2013 Oct; 54(10):1714-9. PubMed ID: 24064821
[No Abstract] [Full Text] [Related]
50. The BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.
Chen X; Liu H; Xing H; Sun H; Zhu P
Nat Med; 2014 Oct; 20(10):1090. PubMed ID: 25295932
[No Abstract] [Full Text] [Related]
51. Reply: the BIM deletion polymorphism cannot account for intrinsic TKI resistance of Chinese individuals with chronic myeloid leukemia.
Ong ST; Chuah CT; Ko TK; Hillmer AM; Lim WT
Nat Med; 2014 Oct; 20(10):1090-1. PubMed ID: 25295933
[No Abstract] [Full Text] [Related]
52. Association between BIM polymorphism and lung cancer outcomes: a meta-analysis.
Li XF; Wu LX; Chen HF; Zhu YC; Wang WX; Xu CW; Lin XP; Xie DF; Du KQ
Cell Mol Biol (Noisy-le-grand); 2018 Aug; 64(11):92-96. PubMed ID: 30213299
[TBL] [Abstract][Full Text] [Related]
53. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
[TBL] [Abstract][Full Text] [Related]
54. Role of EGFR SNPs in survival of advanced lung adenocarcinoma patients treated with Gefitinib.
Zhang L; Yuan X; Chen Y; Du XJ; Yu S; Yang M
Gene; 2013 Mar; 517(1):60-4. PubMed ID: 23313300
[TBL] [Abstract][Full Text] [Related]
55. EGFR dinucleotide repeat polymorphism as a prognostic indicator in non-small cell lung cancer.
Dubey S; Stephenson P; Levy DE; Miller JA; Keller SM; Schiller JH; Johnson DH; Kolesar JM;
J Thorac Oncol; 2006 Jun; 1(5):406-12. PubMed ID: 17409891
[TBL] [Abstract][Full Text] [Related]
56. Apoptosis of non-small-cell lung cancer cell lines after paclitaxel treatment involves the BH3-only proapoptotic protein Bim.
Li R; Moudgil T; Ross HJ; Hu HM
Cell Death Differ; 2005 Mar; 12(3):292-303. PubMed ID: 15711598
[TBL] [Abstract][Full Text] [Related]
57. Different mutation profiles and clinical characteristics among Hispanic patients with non-small cell lung cancer could explain the "Hispanic paradox".
Arrieta O; Ramírez-Tirado LA; Báez-Saldaña R; Peña-Curiel O; Soca-Chafre G; Macedo-Perez EO
Lung Cancer; 2015 Nov; 90(2):161-6. PubMed ID: 26358312
[TBL] [Abstract][Full Text] [Related]
58. Exploratory cohort study and meta-analysis of
Sun S; Yu H; Wang H; Zhao X; Zhao X; Wu X; Qiao J; Chang J; Wang J
Onco Targets Ther; 2017; 10():1955-1967. PubMed ID: 28435285
[TBL] [Abstract][Full Text] [Related]
59. The identification of KRAS mutations at codon 12 in plasma DNA is not a prognostic factor in advanced non-small cell lung cancer patients.
Camps C; Jantus-Lewintre E; Cabrera A; Blasco A; Sanmartín E; Gallach S; Caballero C; del Pozo N; Rosell R; Guijarro R; Sirera R
Lung Cancer; 2011 Jun; 72(3):365-9. PubMed ID: 21074889
[TBL] [Abstract][Full Text] [Related]
60. Analysis of potential predictive markers of cetuximab benefit in BMS099, a phase III study of cetuximab and first-line taxane/carboplatin in advanced non-small-cell lung cancer.
Khambata-Ford S; Harbison CT; Hart LL; Awad M; Xu LA; Horak CE; Dakhil S; Hermann RC; Lynch TJ; Weber MR
J Clin Oncol; 2010 Feb; 28(6):918-27. PubMed ID: 20100958
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]